Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04955639
Other study ID # C-650
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 3, 2021
Est. completion date November 17, 2023

Study information

Verified date January 2024
Source Pivot Health Technologies Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Two-arm, parallel-group, non-crossover, single-center pilot randomized controlled trial, enrolling up to 180 participants to evaluate the effect of the Pivot smoking cessation program (intervention) compared to usual care (commercially available app smoking cessation program plus optional nicotine replacement therapy, control).


Description:

The present pilot randomized controlled trial compares user engagement and retention, change in attitudes towards quitting smoking, change in smoking behavior and participant feedback in adult smokers randomized either to the Pivot (intervention) or commercially available (control) smoking cessation programs. We aim to assess participants' use of Pivot program and commercially available program. There will be a focus on assessing use and engagement, changes in attitudes towards quitting smoking and changes in smoking behavior over the course of the 2-year study, as well as participant feedback on the set-up, design, use experience, and impact of each program.


Recruitment information / eligibility

Status Completed
Enrollment 188
Est. completion date November 17, 2023
Est. primary completion date April 27, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - 21+ years of age - Current daily cigarette smokers (at least 5 cigarettes per day) for the past 12 months - Plans to quit smoking in the next 30 days - Resident of the United States - Able to read and comprehend English - Owns and uses a smart phone compatible with the study app (iPhone 5 and above with operating system (iOS) 12 and above, or, Android 7.0 and above with operating system Android 7.0 and above) - Has daily internet access on smart phone - Comfortable downloading and using smart phone apps - Willing to sign the Informed Consent Form Exclusion Criteria: - Pregnancy (self-reported) - Health contraindications to nicotine replacement therapy (NRT) use (irregular heartbeat, high blood pressure not controlled with medication, heart attack or stroke in last 2 months, pregnant or breast feeding, skin allergies to adhesive tape or serious skin problems, stomach ulcers, history of seizures) - Using other smoking cessation support, including apps and/or actively taking medication to quit smoking - Daily marijuana use - Residence with another person who is a participant in this study - Immediate family member is a participant in this study - Failure to provide contact or collateral information, failure to verify email address, and/or failure to demonstrate videoconference capability - Participation in a previous study sponsored by Carrot Inc.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control
Standard of Care - Control Smoking Cessation Program
Pivot
Pivot Program Smoking Cessation Program

Locations

Country Name City State
United States Pivot Health Technologies, Inc. San Carlos California

Sponsors (1)

Lead Sponsor Collaborator
Jennifer Marler, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average Total App Openings at 12 Weeks App/program engagement is assessed with the self-report of total app openings through the first 12 weeks of the program. Calculated by summing the number of weekly app openings reported by participants weekly. 12 weeks
Secondary Desire to Quit (Yes/no) desire to quit smoking, participant self-report, yes/no 4 weeks
Secondary Change in Expected Difficulty in Staying Quit Expected difficulty to stay quit from smoking. Participants asked: "How difficult do you think it would be to stay smoke free?". Participant self-report on scale 1-10 (1=Really hard to stay quit, 10=Really easy to stay quit) 12 weeks
Secondary Change in Confidence Levels Towards Quitting Smoking Expected success in quitting smoking. Asked: " If you were to quit smoking right now, how successful would you be?". Participant self-report, scale 1-10 (1=Not at all successful, 10=Completely successful). 12 weeks
Secondary Self-Reported Smoking Abstinence participant self-report of 7-day and 30-day point prevalence abstinence (PPA) from smoking cigarettes 12 weeks
Secondary Self-Reported Smoking Abstinence participant self-report of 7-day and 30-day point prevalence abstinence (PPA) from smoking cigarettes 26 weeks
Secondary Self-Reported Smoking Abstinence participant self-report of 7-day and 30-day point prevalence abstinence (PPA) from smoking cigarettes 52 weeks
Secondary Self-Reported Abstinence From All Tobacco Products participant self report of no tobacco product use including: cigarettes, e-cigarettes/vaping, cigars, chew/snuff, pipe, and hookah 12 weeks
Secondary Self-Reported Abstinence From All Tobacco Products Participant self report of no tobacco product use including: cigarettes, e-cigarettes/vaping, cigars, chew/snuff, pipe, and hookah. 26 weeks
Secondary Self-Reported Abstinence From All Tobacco Products Participant self report of no tobacco product use including: cigarettes, e-cigarettes/vaping, cigars, chew/snuff, pipe, and hookah. 52 weeks
Secondary Biochemically Confirmed Abstinence Participants who report they have achieved at least 7-day point prevalence abstinence at 12 weeks will undergo a videoconference visit with study staff in which they provide a witnessed breath sample using a provided personal mobile carbon monoxide breath sensor. Breath sample values less than 10 ppm (parts per million) will be considered consistent with biochemical abstinence. 12 weeks
Secondary Biochemically Confirmed Abstinence Participants who report they have achieved at least 7-day point prevalence abstinence at 26 weeks will undergo a videoconference visit with study staff in which they provide a witnessed breath sample using a provided personal mobile carbon monoxide breath sensor. Breath sample values less than 10 ppm (parts per million) will be considered consistent with biochemical abstinence. 26 weeks
Secondary Biochemically Confirmed Abstinence Participants who report they have achieved at least 7-day point prevalence abstinence at 52 weeks will undergo a videoconference visit with study staff in which they provide a witnessed breath sample using a provided personal mobile carbon monoxide breath sensor. Breath sample values less than 10 ppm (parts per million) will be considered consistent with biochemical abstinence. 52 weeks
Secondary Self-Reported Continuous Abstinence Defined as self-report of 7-day PPA or greater at 12 weeks, 30-day PPA at 26 weeks, and no more than 5 cigarettes during the intervening time period. 26 weeks
Secondary Self-Reported Continuous Abstinence Defined as self-report of 7-day PPA or greater at 12 weeks, 30-day PPA at 26 weeks, and no more than 5 cigarettes during the intervening time period. 52 weeks
Secondary Biochemically Confirmed Continuous Abstinence Defined as self-report of smoking no more than five cigarettes from 12 weeks after enrollment, and biochemical confirmation of abstinence on all previous and present biovalidation tests, with biochemical confirmation defined as:
Participants who report they have achieved at least 7-day point prevalence abstinence at 12 weeks and 26 weeks will undergo a videoconference visit with study staff in which they provide a witnessed breath sample using a provided personal mobile carbon monoxide breath sensor. Breath sample values less than 10 ppm (parts per million) will be considered consistent with biochemical abstinence.
26 weeks
Secondary Biochemically Confirmed Continuous Abstinence Defined as self-report of smoking no more than five cigarettes from 12 weeks after enrollment, and biochemical confirmation of abstinence on all previous and present biovalidation tests, with biochemical confirmation defined as:
Participants who report they have achieved at least 7-day point prevalence abstinence at 12 weeks, 26 weeks, and 52 weeks will undergo a videoconference visit with study staff in which they provide a witnessed breath sample using a provided personal mobile carbon monoxide breath sensor. Breath sample values less than 10 ppm (parts per million) will be considered consistent with biochemical abstinence.
52 weeks
Secondary Proportion With = 50% CPD Reduction The proportion of participants who reduced their cigarettes per day (CPD) by = 50% compared to baseline 26 weeks
Secondary User Satisfaction - User Feedback User satisfaction with the smoking cessation program, specifically its impact on motivation to quit smoking, and the amount of cigarettes smoked per day. Participants were asked: "How has using your assigned program affected your motivation to quit smoking?" and "How has using your assigned program affected the number of cigarettes you smoke per day?" with the answer choices of "increased", "not affected", and "decreased". 2 weeks
Secondary Additional User Feedback User feedback on what they have learned from using their assigned smoking cessation program. Participants were asked "Which of the following best described what you have learned from using your program?" with the answer choices: "I've learned some really unique/key insights into my smoking behavior", "I've learned some things but nothing that impactful", "I have not learned anything from the program", and "I am more confused after using the program". 3 weeks
Secondary User Feedback - Setup and Starting the Program User feedback with the smoking cessation program, specifically ease of set-up and starting of the program (scale of 1-10, higher value equates to easier time setting up and starting use of the program) 12 weeks
Secondary User Feedback User feedback with the smoking cessation program, specifically whether the program helped with their smoking cessation goals (true/false), and whether the program helped them quit smoking (true/false). 26 weeks
Secondary User Feedback: Number of Participants Who Agreed That Their Program Helped Them Quit Smoking User feedback with the smoking cessation program, specifically whether the program helped them quit smoking (true/false). 52 weeks
Secondary User Satisfaction - Net Promoter Score (NPS) User satisfaction with the smoking cessation program, specifically the likelihood of recommending the program to a friend. Measured with a net promoter score (NPS).
Participants are asked "How likely are you to recommend your study program to a friend or colleague?" and answer on a 10-point (1-10) scale (where 1=Not at all likely and 10=Very likely).
NPS was calculated for each study group by subtracting the percentage of respondents who answered =6 (detractors) from the percentage of respondents who answered 9 or 10 (promotors).
NPS formula = %promotor - %detractor NPS has a score range between -100 and 100 (-100 indicates 100% detractors, 100 indicated 100% promotors of the program).
A higher NPS score indicates greater promoters of the program, and thus a greater likelihood of individuals recommending the program to a friend.
4 weeks, 12 weeks, and 26 weeks
Secondary Engagement With Program - Number of Times App Was Opened Collected weekly during the first 12 weeks after enrollment:
o Number of times app opened
Average number of times the app was opened, cumulative over 12 weeks.
12 weeks
Secondary Engagement With Program - Number of Days App Was Opened Collected weekly during the first 12 weeks after enrollment:
o Number of days in which app was opened
Average number of days the app was opened, cumulative over 12 weeks.
12 weeks
Secondary Engagement With Program - Number of Weeks App Was Opened Collected weekly during the first 12 weeks after enrollment:
o Number of weeks in which app was opened
Average number of weeks the app was opened, cumulative over 12 weeks.
12 weeks
Secondary Participant Changes in Self-Efficacy 6-item Smoking Abstinence Self-efficacy Questionnaire (SASEQ) (Spek V, et al. Int.J. Behav. Med. (2013) 20:444-449).
SASEQ score is on a scale of 0-24. Each of the 6 questions is answered on a 5-point Likert scale (0-4). Greater scores indicate greater self-efficacy toward quitting smoking.
12 weeks
Secondary Participant Changes in Self-Efficacy 6-item Smoking Abstinence Self-efficacy Questionnaire (SASEQ) (Spek V, et al. Int.J. Behav. Med. (2013) 20:444-449).
SASEQ score is on a scale of 0-24. Each of the 6 questions is answered on a 5-point Likert scale (0-4). Greater scores indicate greater self-efficacy toward quitting smoking.
52 weeks
Secondary Participant Changes in Self-reported Health and Wellbeing participant self-report, choices for reporting health: excellent, very good, good, fair, or poor 12 weeks
Secondary Self-Reported Nicotine Replacement Therapy (NRT) Use Nicotine replacement therapy (NRT) use assessed with participant orders of NRT 26 weeks
Secondary Self-Reported Nicotine Replacement Therapy (NRT) Use Nicotine replacement therapy (NRT) use assessed with participant orders of NRT 52 weeks
Secondary Adverse Events participant self-report of adverse events and any issues experienced with assigned study app/program as well as the provided nicotine replacement therapy (NRT). For further adverse event details - see adverse event portion of this record. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Not yet recruiting NCT06307496 - VIDeOS for Smoking Cessation N/A
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A